Market: NASD |
Currency: USD
Address: 930 Winter Street
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
📈 Aerovate Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$3.00
-
Upside/Downside from Analyst Target:
9.09%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2025 |
- |
$0.028571 |
- |
2025-04-29 |
- |
Stock split |
$2.400000 |
- |
2025-04-25 |
- |
Dividend payout |
Total Amount for 2025: $2.428571 |
📅 Earnings & EPS History for Aerovate Therapeutics, Inc.
Date | Reported EPS |
---|
2025-04-25 | -3.15 |
2025-02-24 | -6.65 |
2024-11-12 | -19.6 |
2024-08-12 | -30.1 |
2024-05-13 | -29.05 |
2024-03-25 | -25.9 |
2023-11-13 | -24.85 |
2023-08-14 | -26.6 |
2023-05-15 | -23.45 |
2023-03-29 | -21.35 |
2022-11-14 | -19.6 |
2022-08-15 | -17.15 |
2022-05-16 | -15.75 |
2022-03-30 | -2.45 |
2021-11-15 | -9.1 |
2021-08-16 | -8.28 |
📰 Related News & Research
No related articles found for "aerovate therapeutics".